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1. Liver X receptors (LXRs)
Nuclear receptors, such as LXR (liver X receptor), bind to
DNA cis elements, known as hormone response elements, and
activate transcription of their speci¢c target genes [1]. LXR
was originally termed orphan nuclear receptor because its
natural ligand was unknown at the time that it was initially
cloned. With the recent identi¢cation of physiological ligands
that activate LXR, this orphan is now ‘adopted’ [2].
LXR was originally isolated from a human cDNA library
[3], and later two isoforms were identi¢ed, LXRK and LXRL.
Both isoforms bind RXR (9-cis retinoic acid receptor) to form
a heterodimer, and the heterodimers bind to the hormone
response element DR4. Oxidized forms of cholesterol (oxy-
sterols), which are intermediary substrates in the rate-limiting
steps of steroid hormone biosynthesis, of bile acid synthesis,
and in the conversion of lanosterol to cholesterol, have been
identi¢ed as the potential physiological ligands for LXRs [4].
These ¢ndings strongly suggest that LXRs play a role in the
cholesterol homeostasis of the body. Indeed, several impor-
tant genes encoding proteins involved in body cholesterol
transport have been shown to be regulated by LXRs. In ad-
dition, LXRs have also been shown to a¡ect major genes
encoding proteins that control triglyceride metabolism.
Thus, LXRs appear to provide peripheral tissues with fatty
acids while bringing cholesterol back to the liver (Fig. 1).
2. LXRs in reverse cholesterol transport
LXRs appear to control all the major steps in a pathway
called ‘reverse cholesterol transport’. In this process cholester-
ol is transported from extrahepatic tissues into the liver to be
excreted as cholesterol or bile acids into the bile, and ulti-
mately into the gut (for a recent review see [5]). LXRs induce
expression of ABCA1 [6] and ABCG1 [7], which are involved
in transport of cholesterol and phospholipids from cells to
extracellular cholesterol acceptors, notably the lipid-poor apo-
lipoproteins apoAI and apoE. Interestingly, LXRs also induce
expression of apoE in macrophages and adipocytes [8], and so
may enhance reverse cholesterol transport in a tissue-speci¢c
manner. The lipid transfer proteins regulated by LXRs in-
clude the phospholipid transfer protein (PLTP) [9] and cho-
lesterol ester transfer protein (CETP) [10]. PLTP is involved in
the generation of e⁄cient acceptors of cellular cholesterol
(preL-HDL (high density lipoprotein)). In this process,
PLTP transfers excess lipoprotein surface phospholipids (sur-
face remnants) to lipid-poor apolipoprotein A-I (apo A-I).
The remnants are formed when lipoprotein lipase (LPL) hy-
drolyzes triglyceride-rich lipoproteins such as very low density
lipoprotein (VLDL). In addition, PLTP generates preL-HDL
through remodeling of circulating HDL particles. CETP, in
turn, transports cholesteryl esters from HDL particles to the
apolipoprotein B-100-containing lipoprotein particles (VLDL,
intermediate density lipoprotein or IDL, and low density lipo-
protein or LDL). This leads to hepatic clearance of the cho-
lesteryl esters when the IDL and LDL particles are taken up
by the liver. Finally, in the mouse, but not in humans, LXRs
also increase hepatic transcription of 7-K-hydroxylase [11],
which is involved in bile acid synthesis and thus drives secre-
tion of the cholesterol taken up by the liver into the bile.
3. LXRs in triglyceride metabolism
Recent studies have revealed that LXRs are involved in the
regulation of triglyceride metabolism [12,13]. LXRs stimulate
fatty acid synthesis in the liver, and the increased quantities of
fatty acids in the liver cells then become available for the
synthesis of triglycerides, which are subsequently secreted
into the circulation as major components of the triglyceride-
rich lipoproteins (VLDLs). The genes involved in fatty acid
synthesis and activated by the LXRs include the gene encod-
ing the sterol regulatory element-binding protein 1c (SREBP-
1c) and the fatty acid synthase [14]. Moreover, LXRs also
control the synthesis of lipoprotein lipase (LPL) [15], an en-
zyme located on the luminal surface of vascular endothelial
cells. By hydrolyzing triglycerides in triglyceride-rich lipopro-
teins, LPL liberates fatty acids into adipose tissue for storage
and into skeletal muscle for energy expenditure [16]. Thus,
LXRs are involved in fatty acid metabolism by promoting
both their hepatic synthesis and their peripheral uptake.
4. E¡ect of LXRs on murine atherogenesis
In atherosclerosis, lipoprotein-derived cholesterol accumu-
lates in the arterial intima, especially in monocyte-derived
macrophages, which become cholesterol-¢lled and then are
called foam cells. To prevent such accumulation, cholesterol
must be e⁄ciently removed from the macrophages. LXR is
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strongly expressed by arterial macrophages, and, as described
above, plays a major role in controlling cellular cholesterol
e¥ux, the initial step in reverse cholesterol transport. To ex-
plore the role of macrophage LXR in atherogenesis, bone
marrow transplantation has been used in two murine models
of atherosclerosis, the apoE3=3 and the LDLR3=3 mice.
ApoE3=3 mice lack apolipoprotein E, and hence the recep-
tor-mediated hepatic clearance of apoE-containing lipopro-
teins VLDL and IDL is retarded. Therefore, the apoE3=3
mice accumulate large quantities of these lipoproteins in plas-
ma even on normal chow diet and develop atherosclerosis.
Reconstitution of apoE3=3 mice with wild-type bone marrow
leads apoEþ=þ macrophages to populate arterial wall and oth-
er tissues. Such macrophages secrete apoE, which then binds
to the apoE-de¢cient lipoproteins and promotes their clear-
ance from the circulation, ultimately protecting these athero-
sclerosis-susceptible mice from atherogenesis. LDLR3=3 mice
lack LDL receptors, and, due to absent receptor-mediated
hepatic clearance of LDL particles, these animals accumulate
apoB-containing lipoproteins (VLDL, IDL and LDL) in the
plasma. However, these mice develop signi¢cant atherosclero-
sis only when fed a high-fat ‘western’ diet. Since in the
LDLR3=3 mice, (i) an increase in plasma cholesterol is due
to elevation of mainly LDL levels, (ii) the LDL receptor, in
contrast to apoE, plays only a minor role in macrophage
function, and (iii) both genetic and dietary factors are re-
quired to induce atherosclerosis, the LDLR3=3 mice are
thought to re£ect human cardiovascular disease better than
the apoE3=3 mice. Tangirala and coworkers [17] transplanted
wild-type or LXRKL3=3 bone marrow into apoE3=3 mice and
into LDLR3=3 mice. They found that transplantation of
LXRKL3=3 bone marrow cells (macrophages) into atheroscle-
rosis-susceptible mice of either type led to increased athero-
sclerosis as compared with transplantation with wild-type
bone marrow cells [17]. These experiments nicely demon-
strated macrophage LXRs as inhibitors of atherosclerosis.
The physiological relevance of LXR in lipid homeostasis
and atherosclerosis has also been tested in chow-fed
LXRK3=3, LXRL3=3, and LXRKL3=3 mice without other
genetic defects in£uencing lipoprotein metabolism [18]. Inter-
estingly, it was found that, in 18-month-old LXRKL3=3 ani-
mals, cholesterol accumulated in the macrophages of the
spleen, lung, and arterial wall. The levels of all the major
plasma lipoproteins in the double-mutant mice were also af-
fected. Thus, in addition to the expected strong reduction in
the levels of serum triglycerides (VLDL), a subtle decrease in
HDL cholesterol and a signi¢cant increase in LDL cholesterol
were observed in the LXRKL3=3 animals. Since foam cells
were formed in spite of the low triglyceride levels, this ¢nding
would suggest that the LXR target genes encoding the pro-
teins involved in cholesterol metabolism are the critical com-
ponents in the observed atheroprotection of the LXRs. The
data also reveal the potential of the full complement of LXRs
in the mammalian body, i.e. when expressed in the macro-
phages and the liver, they may act in concert to protect the
animals from atherosclerosis.
In the current issue of FEBS Letters, Terasaka et al. [19]
provide pharmacological evidence of a role for LXR in athe-
roprotection. They found that administration of T-0901317, a
synthetic LXR ligand, to LDLR3=3 mice on an atherogenic
diet did not a¡ect the total cholesterol levels, induced a tran-
sient increase in the triglyceride levels, and to some extent
Fig. 1. LXRs in the regulation of lipid homeostasis of the body. The ¢gure shows the various proteins whose regulation is under the control of
LXRs (blue background). LXRs stimulate hepatic fatty acid synthesis by upregulating the SREBP-1c and the fatty acid synthase (FAS). The
fatty acids formed are incorporated into VLDL particles in the form of triglycerides. The triglycerides of VLDL are hydrolyzed into free fatty
acids by LPL in the capillary bed. The resulting LDL particles, the major cholesterol-containing lipoproteins in the circulation, accumulate in
the arterial wall, notably in macrophages, causing the formation of foam cells. E¥ux of unesteri¢ed cholesterol from the macrophages to the
apolipoprotein (apo) AI- or E-containing small phospholipid disks (surface remnants) is facilitated by the ATP-binding cassette transporters A1
and G1 (ABCA1 and ABCG1). The surface remnants are derived from the surface material of the VLDL particles upon action of LPL and
PLTP. Once enriched with unesteri¢ed cholesterol, the surface remnants mature into spherical HDL particles as the unesteri¢ed cholesterol is
esteri¢ed by the enzyme lecithin cholesterol acyl transferase (LCAT). The cholesteryl esters of the HDL particles can be selectively taken up by
the scavenger receptor BI (SR-BI) in the liver or, alternatively, be transported to larger apoB-100-containing lipoprotein particles (LDL) by
CETP. The LDL particles are taken up by the hepatic LDL receptors (LDLR). Cholesterol in the liver can be used for synthesis of VLDL par-
ticles, or can be secreted into the bile, either as such or after being converted into bile acids. In this conversion the enzyme 7-K-hydroxylase
(CYP7A1) is rate-limiting.
FEBS 26940 29-1-03 Cyaan Magenta Geel Zwart
P.T. Kovanen, M.O. Pentika«inen/FEBS Letters 536 (2003) 3^54
corrected the decrease in the HDL levels induced by the athe-
rogenic diet. Most importantly, T-0901317 induced macro-
phage ABCA1 expression in the aortic root and dose-depen-
dently inhibited formation of atherosclerotic lesions (up to
71%). These results are consistent with those of Joseph et al.
[20], who studied the e¡ect of another synthetic LXR ligand,
GW395, on atherosclerosis in both apoE3=3 and LDLR3=3
mice. These workers found that, in the LDLR3=3 mice on a
high-fat diet, GW395 decreased the total cholesterol levels
without a¡ecting the triglycerides, whereas in apoE3=3 mice
on a chow diet, GW395 did not a¡ect the cholesterol levels
but signi¢cantly increased the triglycerides. Despite the di¡er-
ential responses in the plasma lipid levels in the two murine
models of atherosclerosis, formation of atherosclerotic lesions
was decreased in all the mice; byV50% in both the apoE3=3
and the LDLR3=3 male mice and by 35% in the female
LDLR3=3 mice.
5. LXRs ^ good targets for the treatment of atherosclerosis?
Although the e¡ects of LXR agonists on triglyceride me-
tabolism have raised concerns over the use of these agonists in
the treatment of atherosclerosis, the recent long-term experi-
ments by Joseph et al. [20] and Terasaka et al. [19] with two
di¡erent synthetic LXR ligands appear promising, at least in
mice. These experimental studies suggest that the potentially
harmful LXR-dependent changes in triglyceride metabolism
(elevation of plasma triglyceride levels) are e¡ectively counter-
acted by the potentially bene¢cial LXR-dependent variations
in cholesterol metabolism (a decrease in the plasma LDL
cholesterol level and an increase in the plasma HDL level).
Although human studies with LXR agonists are not available,
it is reasonable to assume that the basic physiological princi-
ples of LXR action also apply to the human liver, and that
the opposing e¡ects of LXR agonists on lipid metabolism also
apply to humans. Thus, it is a challenge for the pharmaceut-
ical industry to develop LXR agonists that speci¢cally activate
macrophage LXRs without in£uencing the activity of the
LXRs in the liver. Perhaps the identi¢cation of peroxisome
proliferator-activated receptors as LXR activators [21] will
generate novel pharmacological approaches to stimulate
ABCA1-dependent cholesterol e¥ux from macrophages with-
out increasing the levels of plasma triglyceride-rich lipopro-
teins, or, ideally, lowering their levels.
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